Abstract
DARPins (designed ankyrin repeat proteins), new kinds of binding proteins, have the potential to overcome the defects of monoclonal antibodies, and hence may become the alternatives to antibodies and generate a novel therapeutic approach. DARPins can be selected to bind any given target proteins with high affinity and specificity. In the process of binding to target proteins, the reason why DARPins have high affinity to target proteins as well as the correlation among sequences, structures, dynamical behaviors and binding to target proteins are still unknown. This paper studied DARPins using the AMBER package with ff03 force field for molecular dynamics simulations, providing a theoretical basis for the research on a new type of protein drug. This shows that the DARPins have more dynamical behaviors regularity after binding to target proteins compared with non-binding DARPins, but the binding to target proteins does not always stabilize the structures of DARPins, and the changes in the regions of β-turn and loop are the most obvious. The changes in hydrogen bonds and hydrophobic interactions have close relationship with the changes in the stability and cross correlation of DARPins.
Keywords: Molecular dynamics simulation DARPins protein drug, dynamical cross correlation stability, binding proteins, monoclonal antibodies, alternatives, AMBER package, theoretical basis, target proteins, β-turn, loop
Current Pharmaceutical Design
Title:Exploring the Relationship between Sequences, Structures, Dynamical Behaviors and Functions of New Type Protein Drugs: DARPins
Volume: 19 Issue: 12
Author(s): Xue Wu, Yue Shi, Pengyu Ren, Deping Wang and Guohui Li
Affiliation:
Keywords: Molecular dynamics simulation DARPins protein drug, dynamical cross correlation stability, binding proteins, monoclonal antibodies, alternatives, AMBER package, theoretical basis, target proteins, β-turn, loop
Abstract: DARPins (designed ankyrin repeat proteins), new kinds of binding proteins, have the potential to overcome the defects of monoclonal antibodies, and hence may become the alternatives to antibodies and generate a novel therapeutic approach. DARPins can be selected to bind any given target proteins with high affinity and specificity. In the process of binding to target proteins, the reason why DARPins have high affinity to target proteins as well as the correlation among sequences, structures, dynamical behaviors and binding to target proteins are still unknown. This paper studied DARPins using the AMBER package with ff03 force field for molecular dynamics simulations, providing a theoretical basis for the research on a new type of protein drug. This shows that the DARPins have more dynamical behaviors regularity after binding to target proteins compared with non-binding DARPins, but the binding to target proteins does not always stabilize the structures of DARPins, and the changes in the regions of β-turn and loop are the most obvious. The changes in hydrogen bonds and hydrophobic interactions have close relationship with the changes in the stability and cross correlation of DARPins.
Export Options
About this article
Cite this article as:
Wu Xue, Shi Yue, Ren Pengyu, Wang Deping and Li Guohui, Exploring the Relationship between Sequences, Structures, Dynamical Behaviors and Functions of New Type Protein Drugs: DARPins, Current Pharmaceutical Design 2013; 19 (12) . https://dx.doi.org/10.2174/1381612811319120017
DOI https://dx.doi.org/10.2174/1381612811319120017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Dual-targeting Janus Dendrimer Based Peptides for Bone Cancer: Synthesis and Preliminary Biological Evaluation
Letters in Organic Chemistry Biological Activities of Artemisinin Derivatives Beyond Malaria
Current Topics in Medicinal Chemistry NSAIDs and Chemoprevention
Current Cancer Drug Targets Drug Delivery Approaches for Doxorubicin in the Management of Cancers
Current Cancer Therapy Reviews Preface
Current Cancer Drug Targets Activation of p53 by Specific Agents in Potential Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Autophagy and Apoptosis Specific Knowledgebases-guided Systems Pharmacology Drug Research
Current Cancer Drug Targets Ellagic Acid: Cytodifferentiating and Antiproliferative Effects In Human Prostatic Cancer Cell Lines
Current Pharmaceutical Design Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Steroids and the Endometrium
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Medicinal Chemistry GCPII Variants, Paralogs and Orthologs
Current Medicinal Chemistry Affective Disorder and Hyperandrogenism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Acknowledgements to Reviewers
Anti-Cancer Agents in Medicinal Chemistry Chip-Based High Throughput Screening of Herbal Medicines
Combinatorial Chemistry & High Throughput Screening New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Carrier Deformability in Drug Delivery
Current Pharmaceutical Design